Treatment of relapsed/refractory diffuse large B-cell lymphoma and the real-world data perspective
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10507977" target="_blank" >RIV/00064165:_____/25:10507977 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10507977
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.hSqUaJcE9" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.hSqUaJcE9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.48095/cctahd202528" target="_blank" >10.48095/cctahd202528</a>
Alternative languages
Result language
angličtina
Original language name
Treatment of relapsed/refractory diffuse large B-cell lymphoma and the real-world data perspective
Original language description
Management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has undergone significant transformation in recent years. Second line therapy has shifted from conventional salvage regimens toward immunotherapy-based approaches. CAR T-cell therapy is now the preferred option for patients with early relapse or primary refractory disease, while salvage chemoimmunotherapy followed by autologous stem cell transplantation consolidation remains reserved for younger, fit individuals with late relapses. Bispecific antibodies (BiAbs) combined with chemotherapy (i.e., glofitamab plus GemOx) offer effective alternatives for transplant-ineligible patients. Additional novel options include Pola-BR and tafasitamab-lenalidomide, particularly for elderly or frail individuals. In third line and later settings, treatment is increasingly individualized. CAR T-cell therapy remains the preferred modality if not previously administered; otherwise, BiAbs (glofitamab, epcoritamab, odronextamab), antibody-drug conjugates (loncastuximab tesirine, brentuximab vedotin), and lenalidomide-based regimens are considered. Real-world data from the NiHiL registry support the clinical utility of these novel agents and demonstrate improved survival outcomes following their integration into routine clinical practice.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Transfuze a hematologie dnes
ISSN
1213-5763
e-ISSN
1805-4587
Volume of the periodical
31
Issue of the periodical within the volume
4
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
5
Pages from-to
305-309
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-105028507120